Extended Data Table 2.
Clinical and treatment characteristics of immune checkpoint blockade (ICB) exposed patients with and without development of a subsequent primary malignancy (SPM).
| ICB exposed who developed SPM N=21 | ICB exposed no SPM N=151 | |
|---|---|---|
|
| ||
| Characteristic: | %/N | %/N |
|
| ||
| Pathogenic germline variant: | ||
| MSH6 | 14 (3/21) | 18 (27/151) |
| PMS2 | 0 | 19 (29/151) |
| MSH2 | 57 (12/21) | 36 (54/151) |
| MLH1 | 29 (6/21) | 22 (33/151) |
| EPCAM | 0 | 4 (6/151) |
| MSH2+EPCAM | 0 | 0.7 (1/151) |
| MLH1+MSH2 | 0 | 0.7 (1/151) |
|
| ||
| Rank order of the target tumor: | ||
| 1 | 43 (9/21) | 66 (99/151) |
| 2 | 14 (3/21) | 20 (30/151) |
| 3 | 14 (3/21) | 7 (11/151) |
| 4 | 10 (2/21) | 2 (3/151) |
| 5 | 19(4/21) | 3 (4/151) |
| 7 | - | 1 (2/151) |
| 9 | - | 0.7 (1/151) |
| 10 | - | 0.7(1/151) |
|
| ||
| Extent of disease at the time of ICB exposure | ||
| Local | 33.3 (7/21) | 34 (51/151) |
| Metastatic | 66.7(14/21) | 66 (100/151) |
|
| ||
| Immune checkpoint blockade: | ||
| Single agent PD1i | 81 (17/21) | 80 (121/151) |
| Single agent PDL1i | 5 (1/21) | 11 (16/151) |
| Combination (CTLA4i +PD1i) | 0 | 7 (11/151) |
| Sequential PD1i, Combination (CTLA4i+PD1i) | 9(2/21 | 2 (3/151) |
| Sequential PDL1i, PD1i, Combination (CTLA4i+PD1i) | 5 (1/21) | 0 |
|
| ||
| Patients who received less than 6 months of therapy: | 24 (5/21) | 48 (72/151) |
|
| ||
| Median duration of ICB: | ||
| Time(months) (IQR) | 24 (10–27) | 7 (3–17) |
Given risk of multiple primary cancers in Lynch syndrome, the tumor targeted by the ICB was ranked as to the order in which it had occurred.
IQR: Interquartile range